Insulet Corporation (PODD)
| Market Cap | 20.47B |
| Revenue (ttm) | 2.20B |
| Net Income (ttm) | 402.20M |
| Shares Out | 70.37M |
| EPS (ttm) | 5.55 |
| PE Ratio | 52.42 |
| Forward PE | 65.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,981 |
| Open | 292.96 |
| Previous Close | 292.01 |
| Day's Range | 289.08 - 293.17 |
| 52-Week Range | 173.00 - 329.33 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 320.11 (+10.05%) |
| Earnings Date | Aug 7, 2025 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is cont... [Read more]
Financial Performance
In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price target is $320.11, which is an increase of 10.05% from the latest price.
News
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
ACTON, Mass.--(BUSINESS WIRE)--Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod 5 on Improved Health Outcomes at the American Diabetes Association Conference.
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible wi...
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Outlier Money Flows Lift Insulet
Big Money buying shares of Insulet Corporation (PODD).
Insulet Announces Publication of 2024 Sustainability Report
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to annou...
20 stocks of companies showing excellent earnings-season trends even as the economy cools
With U.S. economic growth turning negative during the first quarter, this earnings season's results might shed some light on which companies may best weather the disruption brought about by President ...
S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks
Major U.S. equities indexes pulled back from their early gains Friday as investors wait for new developments on tariffs ahead of a weekend meeting between U.S. and Chinese officials.
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More
U.S. equities were mixed and little changed at midday as the markets awaited key trade talks between the U.S. and China set for this weekend. The Dow Jones Industrial Average edged lower, while the S&...
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad
Insulet Corporation PODD reported first-quarter adjusted earnings of $1.02 per share, beating the consensus of 80 cents.
Insulet Is the Top S&P 500 Performer Today. Here's Why.
The insulin pump maker beat earnings expectations for the first quarter and raised its forecast for 2025.
Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director, IR Tim Scannell - Chair Ashley McEvoy - President and C...
Insulet beats quarterly profit estimates on insulin pump demand
Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...
Insulet Names New CEO, Expects to Top Revenue Projections
Insulet (PODD) shares edged lower Monday as the maker of an insulin delivery device for diabetes patients announced a shakeup in its leadership.
Insulet Appoints Ashley McEvoy President and CEO
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Ashley McEvoy President and CEO.
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
ACTON, Mass.--(BUSINESS WIRE)--Insulet's RADIANT trial demonstrates meaningful glycemic improvements with Omnipod 5 AID following direct transition from multiple daily injections.
Insulet Announces Pricing of Senior Notes Due 2033
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a ...
Insulet Announces Proposed Financing Transactions
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announc...
Insulet Leans Bullish (Technical Analysis)
PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with th...
Insulet to Host Investor Day on June 5, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Inve...
Insulet Sales Keep Rising
Insulet Corporation (PODD) continues its strong sales and growth trend.